Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H.

Alzheimers Dement. 2014 May 2. pii: S1552-5260(14)00066-1. doi: 10.1016/j.jalz.2014.02.004. [Epub ahead of print] Review.

PMID:
24795085
[PubMed - as supplied by publisher]
2.

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM; Dominantly Inherited Alzheimer Network.

Sci Transl Med. 2014 Mar 5;6(226):226ra30. doi: 10.1126/scitranslmed.3007901.

PMID:
24598588
[PubMed - in process]
3.

Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.

Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM; Alzheimer’s Disease Neuroimaging Initiative.

Biol Psychiatry. 2014 May 1;75(9):723-31. doi: 10.1016/j.biopsych.2013.11.032. Epub 2014 Jan 19.

PMID:
24548642
[PubMed - in process]
4.

Missense variant in TREML2 protects against Alzheimer's disease.

Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, Sassi C, Harari O, Bertelsen S, Lupton MK, Powell J, Bellenguez C, Brown K, Medway C, Haddick PC, van der Brug MP, Bhangale T, Ortmann W, Behrens T, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Haines JL, Turton J, Braae A, Barber I, Fagan AM, Holtzman DM, Morris JC; 3C Study Group; EADI consortium; Alzheimer's Disease Genetic Consortium (ADGC); Alzheimer's Disease Neuroimaging Initiative (ADNI); GERAD Consortium, Williams J, Kauwe JS, Amouyel P, Morgan K, Singleton A, Hardy J, Goate AM, Cruchaga C.

Neurobiol Aging. 2014 Jun;35(6):1510.e19-26. doi: 10.1016/j.neurobiolaging.2013.12.010. Epub 2013 Dec 21.

PMID:
24439484
[PubMed - in process]
5.

Functional connectivity and graph theory in preclinical Alzheimer's disease.

Brier MR, Thomas JB, Fagan AM, Hassenstab J, Holtzman DM, Benzinger TL, Morris JC, Ances BM.

Neurobiol Aging. 2014 Apr;35(4):757-68. doi: 10.1016/j.neurobiolaging.2013.10.081. Epub 2013 Oct 18.

PMID:
24216223
[PubMed - in process]
6.

CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.

Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC.

Neurology. 2013 Dec 3;81(23):2028-31. doi: 10.1212/01.wnl.0000436940.78152.05. Epub 2013 Nov 8.

PMID:
24212387
[PubMed - indexed for MEDLINE]
7.

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease.

Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4502-9. doi: 10.1073/pnas.1317918110. Epub 2013 Nov 5.

PMID:
24194552
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults.

Duchek JM, Balota DA, Thomas JB, Snyder AZ, Rich P, Benzinger TL, Fagan AM, Holtzman DM, Morris JC, Ances BM.

Neuropsychology. 2013 Sep;27(5):516-28. doi: 10.1037/a0033402.

PMID:
24040929
[PubMed - indexed for MEDLINE]
9.

Preclinical Alzheimer's disease criteria.

Fagan AM, Vos SJ.

Lancet Neurol. 2013 Dec;12(12):1134. doi: 10.1016/S1474-4422(13)70222-9. Epub 2013 Sep 9. No abstract available.

PMID:
24025450
[PubMed - indexed for MEDLINE]
10.

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ.

Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6.

PMID:
24016464
[PubMed - in process]
11.

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM.

Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7. Epub 2013 Sep 4.

PMID:
24012374
[PubMed - indexed for MEDLINE]
12.

Progress update: fluid and imaging biomarkers in Alzheimer's disease.

Sutphen CL, Fagan AM, Holtzman DM.

Biol Psychiatry. 2014 Apr 1;75(7):520-6. doi: 10.1016/j.biopsych.2013.07.031. Epub 2013 Sep 5.

PMID:
24012326
[PubMed - in process]
13.

The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.

Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, Bertelsen S, Chibnik L, Schneider JA, Bennett DA; Alzheimer's Disease Neuroimaging Initiative; Genetic and Environmental Risk for Alzheimer's Disease Consortium GERAD, Fagan AM, Holtzman D, Morris JC, Goate AM, Cruchaga C.

PLoS Genet. 2013;9(8):e1003685. doi: 10.1371/journal.pgen.1003685. Epub 2013 Aug 22.

PMID:
23990795
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity.

Wang L, Brier MR, Snyder AZ, Thomas JB, Fagan AM, Xiong C, Benzinger TL, Holtzman DM, Morris JC, Ances BM.

JAMA Neurol. 2013 Oct;70(10):1242-8.

PMID:
23959173
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Impaired default network functional connectivity in autosomal dominant Alzheimer disease.

Chhatwal JP, Schultz AP, Johnson K, Benzinger TL, Jack C Jr, Ances BM, Sullivan CA, Salloway SP, Ringman JM, Koeppe RA, Marcus DS, Thompson P, Saykin AJ, Correia S, Schofield PR, Rowe CC, Fox NC, Brickman AM, Mayeux R, McDade E, Bateman R, Fagan AM, Goate AM, Xiong C, Buckles VD, Morris JC, Sperling RA.

Neurology. 2013 Aug 20;81(8):736-44. doi: 10.1212/WNL.0b013e3182a1aafe. Epub 2013 Jul 24.

PMID:
23884042
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Preclinical Alzheimer disease and risk of falls.

Stark SL, Roe CM, Grant EA, Hollingsworth H, Benzinger TL, Fagan AM, Buckles VD, Morris JC.

Neurology. 2013 Jul 30;81(5):437-43. doi: 10.1212/WNL.0b013e31829d8599. Epub 2013 Jun 26.

PMID:
23803314
[PubMed - indexed for MEDLINE]
17.

Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.

Perrin RJ, Payton JE, Malone JP, Gilmore P, Davis AE, Xiong C, Fagan AM, Townsend RR, Holtzman DM.

PLoS One. 2013 May 20;8(5):e64314. doi: 10.1371/journal.pone.0064314. Print 2013.

PMID:
23700471
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

CSF biomarker variability in the Alzheimer's Association quality control program.

Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Käser SA; Alzheimer's Association QC Program Work Group.

Alzheimers Dement. 2013 May;9(3):251-61. doi: 10.1016/j.jalz.2013.01.010.

PMID:
23622690
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.

Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, Mintun MA, Holtzman DM, Morris JC.

Neurology. 2013 May 7;80(19):1784-91. doi: 10.1212/WNL.0b013e3182918ca6. Epub 2013 Apr 10.

PMID:
23576620
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC; GERAD Consortium; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Goate AM.

Neuron. 2013 Apr 24;78(2):256-68. doi: 10.1016/j.neuron.2013.02.026. Epub 2013 Apr 4.

PMID:
23562540
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk